Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer

PREDICT is an online prognostication tool for early-stage breast cancer, which incorporates human epidermal growth factor 2 (HER2) status and stratifies absolute treatment benefits for hormone therapy, chemotherapy and trastuzumab. The present study compared historical multidisciplinary team (MDT) d...

Descripción completa

Detalles Bibliográficos
Autores principales: DOWN, SUE K., LUCAS, OLIVIA, BENSON, JOHN R., WISHART, GORDON C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214477/
https://www.ncbi.nlm.nih.gov/pubmed/25364461
http://dx.doi.org/10.3892/ol.2014.2589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214477/
https://www.ncbi.nlm.nih.gov/pubmed/25364461
http://dx.doi.org/10.3892/ol.2014.2589

Ejemplares similares